Priya Singhal has sold BIIB and made no open-market buys since Mar 2023

Priya Singhal, M.D., M.P.H., is the Executive Vice President (EVP) and Head of Development at Biogen Inc., a role she assumed in January 2023 after serving as interim Head of Research and Development.( She oversees Biogen's development portfolio, including Japan and China R&D, and rejoined the company in 2020 following prior stints as Senior Vice President of Global Development and Vice President of Clinical Trials and Benefit-Risk Management, where she contributed to filings and approvals for multiple products.(

Dr. Singhal's career spans key roles at Zafgen Inc. as Head of R&D and Manufacturing, Vertex Pharmaceuticals as Vice President of Medical Affairs and in Global Patient Safety, and Millennium Pharmaceuticals leading benefit-risk for Velcade.( Originally from Mumbai, India, she trained in Internal Medicine there, moved to the U.S. in 1995, earned her M.P.H. in International Health from Harvard School of Public Health, and re-entered the workforce after raising her children, rising quickly in biotechnology.(

Written by Perplexity from public sources.